OR WAIT null SECS
© 2021 MJH Life Sciences and Applied Clinical Trials Online. All rights reserved.
© 2021 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
September 27, 2021
Critics say FDA is either acting too fast and risking public safety—or too slow—mired in rules while ignoring important scientific findings.
Biosimilar approvals and the advance of biosimilar testing and production may lead to greater access to alternative therapies.
September 21, 2021
If the debate over vaccines for adults and the need for extra booster shots has been heated, FDA will face even more scrutiny over the safety and value of vaccinating children under age 12.
September 20, 2021
FDA’s Vaccines and Related Biological Products Advisory Committee announces its recommendations for the authorization of a third dose of the Pfizer/BioNTech Comirnaty vaccine.
September 17, 2021
Democrats failed to gain sufficient support this week to advance long-debated legislation to permit Medicare drug price negotiations.
September 14, 2021
FDA is launching a program to test the safety and suitability of novel inactive ingredients for use in new drugs and biologics.
September 10, 2021
White House officials recently announced a nearly $3 billion program to ramp up production of vaccines and their components to better serve patients in the U.S. and globally.
September 02, 2021
A report from the bipartisan Congressional Budget Office analyzes how drug pricing policies could reduce the number of new therapies coming to market.
August 30, 2021
FDA has revealed its plan for revising and renewing its fee program for drugs and biologics.
August 24, 2021
The first COVID-19 vaccine, Comirnaty, has received FDA approval. How will vaccination rates be effected?